Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
CTMX
Stock Latest News
Ratings
Buy Rating for CytomX Therapeutics’ CX-2051 Based on Promising Colorectal Cancer Treatment Potential
18d ago
CTMX
Premium
The Fly
CytomX Therapeutics price target raised to $10 from $5 at H.C. Wainwright
1M ago
CTMX
Premium
The Fly
CytomX Therapeutics price target raised to $6.50 from $5 at Piper Sandler
1M ago
CTMX
Premium
Company Announcements
CytomX Therapeutics Earnings Call Highlights Clinical Progress
1M ago
CTMX
Premium
Company Announcements
CytomX Therapeutics Reports Q3 2025 Financial Results
2M ago
CTMX
Premium
The Fly
CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)
2M ago
CTMX
Premium
Company Announcements
CytomX Therapeutics Advances CX-2051 Study in Solid Tumors
2M ago
CTMX
Premium
Ratings
Cautious Hold Rating on CytomX Therapeutics Amid Safety Concerns and Awaited Phase 1 Data for CX-2051
2M ago
CTMX
Premium
The Fly
CytomX Therapeutics management to meet with Oppenheimer
2M ago
CTMX
Premium
The Fly
CytomX Therapeutics price target raised to $6 from $3.50 at Barclays
2M ago
CTMX
Premium
The Fly
CytomX Therapeutics appoints Rachael Lester as chief business officer
2M ago
CTMX
Premium
The Fly
Oppenheimer positive on CytomX after Merus colon cancer data
2M ago
CTMX
MRUS
Premium
Ratings
CytomX Therapeutics: Hold Rating Amid Awaited CX-801 Data and Market Potential
3M ago
CTMX
Premium
The Fly
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
3M ago
CTMX
Premium
The Fly
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
3M ago
CTMX
Premium
The Fly
CytomX Therapeutics assumed with an Overweight at Barclays
3M ago
CTMX
Premium
The Fly
CytomX Therapeutics initiated with an Overweight at Barclays
3M ago
CTMX
Premium
The Fly
Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event
4M ago
CTMX
Premium
The Fly
CytomX trial ongoing despite grade five event, says Oppenheimer
4M ago
CTMX
Premium
Company Announcements
CytomX Therapeutics Updates on CX-2051 Phase 1 Study
4M ago
8K
CTMX
Premium
The Fly
CytomX Therapeutics provides update on CX-2051 Phase 1 study
4M ago
CTMX
Premium
Company Announcements
CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength
4M ago
CTMX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
